Form 8-K





Washington, D.C. 20549







Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): June 11, 2014



bluebird bio, Inc.

(Exact name of registrant as specified in its charter)




DELAWARE   001-35966   13-3680878

(State or other jurisdiction

of incorporation)



File Number)

  (I.R.S. Employer
Identification No.)


150 Second Street

Cambridge, MA

(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code (339) 499-9300

Not Applicable

(Former name or former address, if changed since last report)



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))




Item 5.07. Submission of Matters to a Vote of Security Holders

On June 11, 2014, bluebird bio, Inc. (the “Company”) held its previously announced Annual Meeting of Stockholders (the “Meeting”), at which a quorum was present. At the Meeting, the stockholders of the Company voted on the two proposals as follows: (i) to elect Steven Gillis and Nick Leschly as Class I members of the board of directors to serve until the Company’s 2017 annual meeting of stockholders (“Proposal 1”) and (ii) to ratify the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2014 (“Proposal 2”).

The Company’s stockholders approved Proposal 1. The votes cast at the Annual Meeting were as follows:


    On the election of Steven Gillis as a Class I director – 20,553,755 shares voted for and 7,389 shares withheld.


    On the election of Nick Leschly as a Class I director – 20,553,775 shares voted for and 7,369 shares withheld.

The Company stockholders approved Proposal 2. The votes cast at the Annual Meeting were as follows: 20,554,380 shares voted for, 6,764 shares voted against and zero shares abstained from voting. There were zero broker non-votes with respect to Proposal 2.


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Date: June 11, 2014     bluebird bio, Inc.

/s/ Jason F. Cole

      Jason F. Cole
      Senior Vice President, General Counsel